AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04995705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT is a psychological intervention. ACT encourages individuals to remain open to internal experiences (positive, negative and neutral), rather than attempting to control or ameliorate them (which may only serve to increase pain and suffering). It also encourages individuals to focus on committing to a life that is congruent with their core values, regardless of the experiences that show up for them. The premise of this model is to learn to modify the relationship one has with their internal experiences (thoughts, feelings, physical sensations etc.), rather than change the experiences per se. This is achieved through different processes including mindfulness, acceptance, defusion and exploration of values. These core tenets of ACT help to cultivate psychological flexibility.~This ACT intervention is delivered as a 5-week group for stroke survivors and adults with brain injury. It comprises of experiential and didactic components.
Study NCT04995705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT is a psychological intervention. ACT encourages individuals to remain open to internal experiences (positive, negative and neutral), rather than attempting to control or ameliorate them (which may only serve to increase pain and suffering). It also encourages individuals to focus on committing to a life that is congruent with their core values, regardless of the experiences that show up for them. The premise of this model is to learn to modify the relationship one has with their internal experiences (thoughts, feelings, physical sensations etc.), rather than change the experiences per se. This is achieved through different processes including mindfulness, acceptance, defusion and exploration of values. These core tenets of ACT help to cultivate psychological flexibility.~This ACT intervention is delivered as a 5-week group for stroke survivors and adults with brain injury. It comprises of experiential and didactic components.
Study NCT03895723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic and robotic liver resection
Description: laparoscopic and robotic procedure for liver resection
Study NCT03895723 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: open surgery
Description: using open surgery procedure for liver resection
Study NCT02715583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Acetate
Study NCT02080286 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prism Adaptation
Description: All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
Study NCT02080286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prism Adaptation
Description: All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
Study NCT02080286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy.
Study NCT02080286 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy.
Study NCT04183946 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online Cognitive Behavioural Therapy
Description: The Willkommen Mutterglück program is an 8-session, interactive web-based CBT intervention for prenatal and postpartum depression and anxiety. The sessions are administered online via audio and video images. Each weekly session has a duration of 40-50 minutes during which the participants are asked to actively participate through exercises and quizzes.~A SCID interview for screening will be conducted by a trained clinical psychologist and an experienced psychiatrist from our outpatient clinic will verify the diagnosis. Screened and consented participants will answer baseline questionnaires, provide sociodemographic information and receive a private login to access the program. After completing the 2nd, 4th and 8th intervention session participants will fill in psychological questionnaires.~During the intervention, participants will be contacted three times by telephone by coaches (psychotherapists in training) who follow a manualized script.
Study NCT02881983 — intervention group
Intervention type: OTHER
Intervention: the presentation of pictures (static stimuli) or videos (dynamic stimuli)
Study NCT00507585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 60 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
Study NCT02054065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAUTI Decision Support
Description: Decision support used to prevent Catheter Associated Urinary Tract Infections
Study NCT02607124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Study NCT01985334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA
Description: Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
Study NCT01985334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMA
Description: Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
Study NCT01985334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS
Description: Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
Study NCT00243503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248/Trastuzumab
Description: SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
Study NCT01546753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Walnut Protein Powder
Description: Blinded study product dosing begins with a 1-day oral desensitization protocol to walnut for subjects in the active arm. Starting at 0.1 mg protein and increasing to a maximum of 6 mg or until allergic symptoms develop. Subjects continue daily dosing of blinded OIT (walnut) with build-up every 2 weeks to a maximum daily dose of 1500mg at week 34, followed by 4 weeks of daily maintenance dosing. OFC to walnut and second tree nut occurs at week 38 then treatment is unblinded and open-label maintenance dosing occurs.
Study NCT01546753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oat Powder (placebo)
Description: Blinded study product dosing begins with a one-day oral desensitization protocol with placebo (oat) powder. Subjects in the placebo group will undergo the same protocol as those in the active group with placebo OIT dosing. Unblinding to treatment assignment will occur after the 38 week oral food challenge. Placebo subjects will cross-over to active, open-label treatment with walnut powder after the 38 week oral food challenge. beginning with initial escalation day, through build-up and maintenance dosing per the same protocol sequence as noted for active, walnut powder. Subjects will complete an oral food challenge to walnut and the second tree nut at week 38 then will continue on long-term, open-label maintenance dosing until the end of study using same protocol design.
Study NCT01546753 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Open-label Walnut Protein Powder
Description: Open-label treatment phase begins after the 38 week oral food challenge with unblinding of treatment assignment. For those on active treatment, daily maintenance dosing occurs for up to a total of 298 weeks. For those on placebo treatment, cross-over to active, open-label treatment occurs using the same active treatment protocol. Placebo-crossover subjects will complete an oral food challenge to walnut and the second tree nut at week 38 of active therapy then continue on long-term, open-label maintenance dosing until the end of study using same protocol design. All subjects may reach a qualifying IgE to walnut/second tree nut early and will undergo an OFCs on and 4 weeks off OIT. All subjects will have OFCs on and 4 weeks off OIT at week 142 and at week 298, unless both walnut/second tree nut OFCs are passed at previous OFC prompting addition of these foods into the diet.
Study NCT01664247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered s.c. (under the skin) once daily. Dose individually adjusted.
Study NCT01664247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered s.c. (under the skin) once daily. Dose individually adjusted.
Study NCT02652806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Study NCT02652806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Study NCT03576833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elipse Balloon system
Description: intragastic balloon
Study NCT01040754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
Study NCT01770899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Study NCT01770899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsule given every 24 hours
Study NCT01184846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10% liquid formulation of human immunoglobulin
Study NCT04372043 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Sleep Hygiene Index and demographic questions.
Study NCT04225884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DTx for pain software
Description: Software with active intervention
Study NCT04225884 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control software
Description: Software without active intervention
Study NCT04225884 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Pain medication
Study NCT02151682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release
Study NCT02151682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine prolonged release
Study NCT02666508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plaque identifying toothpaste
Description: Plaque identifying toothpaste with targetol
Study NCT02666508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-plaque identifying toothpaste
Description: Non-plaque identifying toothpaste without targetol
Study NCT02533193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERAS perioperative cares
Description: 1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Drug: Oral Carbohydrate Solution (OCS). Take 250ml OCS orally 2 hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - liquid diet, 2 days - semifluid diet (SFD), 3 days - normal diet)~7. Intravenous patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. No nasogastric tube~10. No drain insertion~11. Patients will be discharged at POD#4 if there's no problem
Study NCT02533193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional perioperative cares
Description: 1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Drainage tube insertion if needed
Study NCT02420301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuina exercises
Study NCT02420301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tuina exercises
Study NCT01664247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
Study NCT01541501 — intervention group
Intervention type: DEVICE
Intervention: Pachymetry
Description: Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
Study NCT04378699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMR (12-15 Hz)
Description: SMR training sessions (12-15 Hz) C4 unipolar placement, central region
Study NCT04378699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alpha band (8 -12Hz)
Description: 3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
Study NCT03217201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Glasses (Experimental)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
Study NCT03217201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light Glasses (Comparison)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
Study NCT00742521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glucose clamp
Description: Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
Study NCT00742521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glucose clamp
Description: Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
Study NCT01306032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
Study NCT01306032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT03683524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).
Description: bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
Study NCT03683524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current ART
Description: To continue with their current ART
Study NCT04314414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRC brief motivational interview intervention
Description: The intervention will involve the following elements: establishing rapport, asking permission to discuss drugs, discussing the pros and cons associated with drug use, uncovering the gaps between current and desired quality of life and determining readiness to change. The intervention will last approximately 20 minutes and take place at the time of the clinical visit while participants are waiting to be seen by a clinician or are awaiting laboratory testing.
Study NCT04314414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone contact
Description: The PRC will remain in at least weekly contact by phone with each participant.
Study NCT01367652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg tablet
Study NCT01367652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg Tablet
Study NCT04279366 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lifestyle intervention
Description: The 14 week courses takes place at a Danish folk high school (Ubberup), specialized in lifestyle interventions targeting a 10% weight loss. Adult individuals with obesity sign up for the course. They stay at the School for the whole course period and the total cost amounts to 300-400 Euros per week plus loss of income.
Study NCT03049995 — intervention group
Intervention type: PROCEDURE
Intervention: Left ventricular contractile reserve SE
Description: Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.
Study NCT03049995 — intervention group
Intervention type: PROCEDURE
Intervention: B-lines SE
Description: SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.
Study NCT03049995 — intervention group
Intervention type: PROCEDURE
Intervention: Left ventricular outflow tract gradient SE
Description: SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).
Study NCT03025490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnographic monitoring
Description: Capnographic monitoring is used during the sedation.
Study NCT02397642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Study NCT02397642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin
Description: given in different doses and timing to support the luteal phase
Study NCT00093015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume and dose frequency changes resembling dosing in the active treatment group
Study NCT00093015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL
Study NCT00520546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-Ethylcholine Positron Emission Tomography (FEC-PET)
Description: PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq \[18F\]Fluoroethylcholine chloride (FEC; Eckert \& Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure.
Study NCT00520546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)
Description: The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
Study NCT03348371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: The intervention is two different administrationforms of ethanol, orally and i.v.